AzurRx BioPharma, Inc.
AZRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.16 | 0.04 | 0.00 |
| FCF Yield | -15.01% | -0.33% | -4.98% | 62.80% |
| EV / EBITDA | -4.30 | -27.03 | -20.96 | -2.66 |
| Quality | ||||
| ROIC | -0.91% | -1.14% | -1.43% | -1.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.05 | 0.65 | 0.23 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1,459.26% | 93.30% | -111.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | -1.30 | -0.95 | 0.01 |
| Interest Coverage | 25.92 | -17.71 | -45.88 | 1.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |